| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1,557.2 | 1,366.0 |
| Profit before tax | -688.8 | 482.3 |
| Net income | -784.8 | 424.2 |
| EPS (diluted, $ a share) | $-3.86 | $2.11 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +14.0% |
|---|---|
| Operating margin | -45.5% |
10-Q filed with the SEC, NASDAQ: INCY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Incyte Corp: key numbers
- Share price
- $120.27Close, Nov 16
- Market cap
- $24.5B
- Shares outstanding
- 203.83MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Commercial Physical & Biological ResearchSIC 8731
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Incyte Corp
All →Incyte Business Update
Incyte Corporation has decided not to proceed with its planned Phase 3 MAESTRA-3 study of INCB123667 in combination with bevacizumab for ovarian cancer. The decision was based on internal portfolio prioritization rather than safety or efficacy concerns and is not expected to impact the company's financial guidance.
Incyte CMO & Head of Late-Stage Dev. Steven H. Stein Sells $28.4M of Stock
Steven H. Stein, CMO & Head of Late-Stage Dev., sold 240,193 shares of Incyte Corp at $116.06 to $119.66 a share (average $118.39) in 5 transactions, worth $28.4M in total on Nov 6, 2026. Shares held after the trade: 30,916 (-61.1%).
- Value
- $28.4M
- Shares
- 240,193
- Average price
- $118.39
- Role
- CMO & Head of Late-Stage Dev.
- Holding change
- -61.1%
- Trade date
- Nov 6, 2026
Incyte Principal Accounting Officer Thomas Tray Sells $72.6K of Stock
Thomas Tray, Principal Accounting Officer, sold 610 shares of Incyte Corp at $118.96 a share, worth $72.6K in total on Nov 3, 2026. Shares held after the trade: 21,126 (-2.8%).
- Value
- $72.6K
- Shares
- 610
- Price
- $118.96
- Role
- Principal Accounting Officer
- Holding change
- -2.8%
- Trade date
- Nov 3, 2026
Incyte Financial Results
Incyte reported third quarter 2026 total revenue of $1.56 billion, a 14% year-over-year increase driven by strong sales of Jakafi ($827M) and Opzelura ($255M). The company raised its full-year 2026 financial guidance for total net sales and key product portfolios. Results were impacted by a one-time $1.23 billion R&D expense related to the acquisition of Vega Therapeutics.
- Term
- Q3 2026
“Our third quarter was marked by strong commercial performance, meaningful pipeline progress and important regulatory achievements. Net sales growth was strong in both the U.S. and internationally, creating a durable core business beyond Jakafi.”
Bill Meury, Chief Executive Officer, Incyte
Incyte President, Global Head of R&D Pablo J. Cagnoni Sells $298K of Stock
Pablo J. Cagnoni, President, Global Head of R&D, sold 2,642 shares of Incyte Corp at $112.71 a share, worth $298K in total on Oct 15, 2026. Shares held after the trade: 183,200 (-1.4%).
- Value
- $298K
- Shares
- 2,642
- Price
- $112.71
- Role
- President, Global Head of R&D
- Holding change
- -1.4%
- Trade date
- Oct 15, 2026